Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P78356

UPID:
PI42B_HUMAN

ALTERNATIVE NAMES:
1-phosphatidylinositol 5-phosphate 4-kinase 2-beta; Diphosphoinositide kinase 2-beta; Phosphatidylinositol 5-phosphate 4-kinase type II beta; PtdIns(5)P-4-kinase isoform 2-beta

ALTERNATIVE UPACC:
P78356; Q5U0E8; Q8TBP2

BACKGROUND:
The enzyme Phosphatidylinositol 5-phosphate 4-kinase type-2 beta, with alternative names such as Diphosphoinositide kinase 2-beta, is integral to phosphatidylinositol 4,5-bisphosphate synthesis. It distinctively uses GTP for PI(5)P phosphorylation, reflecting its critical role in adapting to changes in GTP levels. Moreover, it negatively regulates insulin signaling, underscoring its significance in metabolic regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Phosphatidylinositol 5-phosphate 4-kinase type-2 beta offers a pathway to novel therapeutic approaches. Given its regulatory role in insulin signaling and metabolic adaptation, targeting this enzyme could lead to breakthroughs in treating metabolic diseases, making it a focal point for drug discovery efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.